{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:55:38Z","timestamp":1792612538213,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.autrev.2014.02.004","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T21:54:31Z","timestamp":1395438871000},"page":"751-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper"],"prefix":"10.1016","volume":"13","author":[{"given":"Gionata","family":"Fiorino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2014.02.004_bb0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","article-title":"Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.autrev.2014.02.004_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000233234","article-title":"Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis","volume":"219","author":"Bansback","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2014.02.004_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","article-title":"Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data","volume":"30","author":"Bodger","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2014.02.004_bb0025","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12325-012-0035-7","article-title":"Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis","volume":"29","author":"Liu","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2014.02.004_bb0030","first-page":"S102","article-title":"Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues","volume":"30","author":"Lapadula","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0035","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.autrev.2013.02.005","article-title":"Is it time for biosimilars in autoimmune diseases?","volume":"12","author":"Cuadrado","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.02.004_bb0040","series-title":"Procedural advice for users of the centralised procedure for similar biological medicinal products applications","author":"European Medicine Agency","year":"2011"},{"key":"10.1016\/j.autrev.2014.02.004_bb0045","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.02.004_bb0050","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.drudis.2011.09.018","article-title":"Effective pharmaceutical regulation needs alignment with doctors","volume":"17","author":"Ebbers","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.autrev.2014.02.004_bb0055","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nbt.1936","article-title":"Biosimilars\u2014why terminology matters","volume":"29","author":"Weise","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0060","series-title":"ICH Topic Q5E","article-title":"Comparability of biotechnological\/biological products: note for guidance on biotechnological\/biological products subject to changes in their manufacturing process","year":"2003"},{"key":"10.1016\/j.autrev.2014.02.004_bb0065","series-title":"Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues","author":"European Medicine Agency","year":"2005"},{"key":"10.1016\/j.autrev.2014.02.004_bb0070","series-title":"Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues","author":"European Medicine Agency","year":"2005"},{"key":"10.1016\/j.autrev.2014.02.004_bb0075","series-title":"Procedural advice for users of the centralised procedure for similar bio-logical medicinal products applications","author":"European Medicine Agency","year":"2013"},{"key":"10.1016\/j.autrev.2014.02.004_bb0080","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.2438","article-title":"Interchangeability, immunogenicity and biosimilars","volume":"30","author":"Ebbers","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0085","author":"Agenzia Italiana del Farmaco"},{"key":"10.1016\/j.autrev.2014.02.004_bb0090","author":"Agenzia Italiana del Farmaco"},{"key":"10.1016\/j.autrev.2014.02.004_bb0095","author":"World Health Organization"},{"key":"10.1016\/j.autrev.2014.02.004_bb0100","author":"Yoo"},{"key":"10.1016\/j.autrev.2014.02.004_bb0105","author":"Park"},{"key":"10.1016\/j.autrev.2014.02.004_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","article-title":"Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?","volume":"16","author":"Lee","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.autrev.2014.02.004_bb0115","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.02.004_bb0120","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.02.004_bb0125","author":"Food and Drug Administration"},{"key":"10.1016\/j.autrev.2014.02.004_bb0130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.beha.2005.01.016","article-title":"Immunologic mechanisms of EPO-associated pure red cell aplasia","volume":"18","author":"Schellekens","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0135","author":"World Health Organization"},{"key":"10.1016\/j.autrev.2014.02.004_bb0140","first-page":"1","article-title":"Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications","volume":"18","author":"Flood","year":"2009","journal-title":"Manag Care"},{"key":"10.1016\/j.autrev.2014.02.004_bb0145","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/j.1468-3083.2012.04450.x","article-title":"Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry","volume":"27","author":"Gisondi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0150","doi-asserted-by":"crossref","first-page":"E467","DOI":"10.1208\/aapsj070247","article-title":"Evidence of effectiveness: how much can we extrapolate from existing studies?","volume":"7","author":"Lee","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.autrev.2014.02.004_bb0155","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2165\/11593730-000000000-00000","article-title":"Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations","volume":"71","author":"Dranitsaris","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2014.02.004_bb0160","author":"European Medicine Agency"},{"key":"10.1016\/j.autrev.2014.02.004_bb0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrgastro.2013.31","article-title":"First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?","volume":"10","author":"Peyrin-Biroulet","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0170","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2014.02.004_bb0175","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2014.02.004_bb0180","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2014.02.004_bb0185","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.02.004_bb0190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.02.004_bb0195","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation?","volume":"62","author":"Gecse","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2014.02.004_bb0200","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2014.02.004_bb0205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12325-012-0072-2","article-title":"Epoetin biosimilars in Europe: five years on","volume":"30","author":"Mikhail","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2014.02.004_bb0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2012-202941","article-title":"Biosimilars in rheumatology: the wind of change","volume":"72","author":"Schneider","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.02.004_bb0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.02.004_bb0220","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.4049\/jimmunol.161.8.3862","article-title":"Therapy with monoclonal antibodies. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function","volume":"161","author":"Isaacs","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.02.004_bb0225","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/sim.5612","article-title":"Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins","volume":"32","author":"Li","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.autrev.2014.02.004_bb0230","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2014.01.051","article-title":"Putting the value into biosimilar decision making: the judgment value criteria","volume":"13","author":"Mendes de Abreu","year":"2014","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:12:17Z","timestamp":1761599537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1568997214000937"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.02.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}